No we don't really disagree, but LLY proceeded over the entire program from phase1 to phase 3 with no real sign of efficacy in cognition. I read and much appreciated your analysis back in 2015. All of the pharmas have gone into expensive phase3 testing with no attempt to run a decent phase 2 program to explore for that efficacy. I guess ELAN did try with BAPI, but they started the phase3 before the phase2 ended, which subsequently failed to demonstrate any cognition benefit.
With LLY it was about biomarkers from the start and they were wrong. I just hope they got some useful info from that program.
PBT2 has demonstrated some nice phase2 cognition signals, with a great safety profile, and the FDA has obstructed it. Go figure.
No we don't really disagree, but LLY proceeded over the entire...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 574591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |